The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Follicular lymphoma: is RELEVANCE relevant?
Dr Franck Morschhauser, of Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France, discusses the question: is RELEVANCE relevant? He covers the results of the Phase III study (NCT01476787) of R2 vs R-chemo in first-line follicular lymphoma. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.
